Osemozotan
Alternative Names: MKC-242; MN-305Latest Information Update: 11 Dec 2025
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Tanabe Pharma Corporation
- Class Antidepressants; Anxiolytics; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Anxiety disorders; Generalised anxiety disorder; Insomnia; Irritable bowel syndrome; Major depressive disorder